Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer

Rafael Selbach Scheffel; Andre Borsatto Zanella; Carla Fernanda Nava; Lenara Golbert; Souza Meyer Erika Laurini de; Marcia Punales; Iracema Goncalves; Jose Miguel Dora; Ana Luiza Maia

doi:10.1530/endoabs.56.GP245

GP245

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 GP245 | DOI: 10.1530/endoabs.56.GP245

ECE2018 Guided Posters Thyroid Cancer - Translational (10 abstracts)

Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer

Rafael Selbach Scheffel ¹ , André Borsatto Zanella ^1, , Carla Fernanda Nava ¹ , Lenara Golbert ³ , Erika Laurini de Souza Meyer ³ , Márcia Punales ⁴ , Iracema Gonçalves ⁴ , José Miguel Dora ¹ & Ana Luiza Maia ¹

Err

Author affiliations

¹Thyroid Unit, Faculdade de Medicina, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; ²Endocrine Division, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; ³Endocrine Division, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil; ⁴Instituto da Criança com Diabetes e Hospital Criança Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil.

Context: Risk stratification for persistent disease is an important step in pediatric differentiated thyroid cancer (DTC) management. The dynamic risk stratification (DRS) is a well validated system for adults, but not yet for children and adolescents.

Objective: To evaluate DRS performance and other prognostic factors in pediatric DTC.

Design: Cohort study.

Setting: Four DTC referral centers at tertiary teaching hospitals.

Patients: Patients aged ≤ 18 years at the time of DTC diagnosis.

Main outcome measures: All patients were classified according to risk stratification system of the 2015 ATA Children DTC guidelines. Patients were also classified according to DRS (excellent, indeterminate, biochemical, or structural incomplete responses). Disease status was evaluated after initial therapy and at last follow-up.

Results: Sixty-six patients were studied: 54 (81.8%) girls, age 14.5±3.0 years, 62(93.9%) papillary thyroid carcinomas. Tumor size was 2.3 cm (P25-75,1.6-3.5), and 41 (63.1%) had cervical and 18 (27.7%) distant metastasis at diagnosis. All patients underwent total thyroidectomy and 63 (95.5%) received radioiodine. Patients were classified according to DRS after initial therapy (n=63) as follows: 21 (33%) excellent, 13 (21%) indeterminate, 6 (9%) biochemical, and 23 (37%) structural incomplete responses. Notably, after 6.0 years (P25-75,2.7-10.0), most patients remained in the same category. Prognostic factors associated with persistent disease in the univariate analysis were TNM, ATA risk, DRS and stimulated postoperative thyroglobulin (sPOTg). Interestingly, the sPOTg cutoff of 37.8 ng/mL displayed 81% sensitivity and 100% specificity to predict excellent response.

Conclusion: DRS after initial therapy and sPOTg are strong predictors of disease status and might be helpful on defining follow-up strategies in pediatric DTC.